Details for New Drug Application (NDA): 219850
✉ Email this page to a colleague
The generic ingredient in BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.
Summary for 219850
| Tradename: | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE |
| Applicant: | Ascent Pharms Inc |
| Ingredient: | buprenorphine hydrochloride; naloxone hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 219850
| Mechanism of Action | Opioid Antagonists Partial Opioid Agonists |
Suppliers and Packaging for NDA: 219850
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | buprenorphine hydrochloride; naloxone hydrochloride | FILM;BUCCAL, SUBLINGUAL | 219850 | ANDA | Camber Pharmaceuticals, Inc. | 31722-479 | 31722-479-30 | 30 POUCH in 1 CARTON (31722-479-30) / 1 FILM, SOLUBLE in 1 POUCH (31722-479-31) |
| BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | buprenorphine hydrochloride; naloxone hydrochloride | FILM;BUCCAL, SUBLINGUAL | 219850 | ANDA | Camber Pharmaceuticals, Inc. | 31722-480 | 31722-480-30 | 30 POUCH in 1 CARTON (31722-480-30) / 1 FILM, SOLUBLE in 1 POUCH (31722-480-31) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | FILM;BUCCAL, SUBLINGUAL | Strength | EQ 2MG BASE;EQ 0.5MG BASE | ||||
| Approval Date: | Jan 21, 2026 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | FILM;BUCCAL, SUBLINGUAL | Strength | EQ 4MG BASE;EQ 1MG BASE | ||||
| Approval Date: | Jan 21, 2026 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | FILM;BUCCAL, SUBLINGUAL | Strength | EQ 8MG BASE;EQ 2MG BASE | ||||
| Approval Date: | Jan 21, 2026 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
